Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.40 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544572 | 0.92 | EGFR (0.40) | EGFRCSF1RTYK2ROCK2CCNT1 | |
| SCHEMBL29545092 | 0.91 | EGFR (0.39) | EGFRCSF1RTYK2CCNT1CDK9 | |
| SCHEMBL29544468 | 0.91 | EGFR (0.41) | EGFRTYK2ROCK2CCNT1CDK9 | |
| SCHEMBL29544798 | 0.89 | EGFR (0.38) | EGFRCSF1RTYK2CCNT1CDK9 | |
| SCHEMBL29544647 | 0.87 | EGFR (0.40) | EGFR | |
| SCHEMBL29545142 | 0.85 | CSF1R (0.39) | EGFRCSF1RTYK2CCNT1CDK9 | |
| SCHEMBL29544775 | 0.83 | EGFR (0.47) | EGFRROCK2 | |
| SCHEMBL29544736 | 0.83 | EGFR (0.40) | EGFRTYK2CCNT1CDK9 | |
| SCHEMBL29544955 | 0.83 | EGFR (0.39) | EGFRCSF1RTYK2CCNT1CDK9 | |
| SCHEMBL29544781 | 0.82 | CCNT1 (0.34) | EGFRCSF1RTYK2CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022072634-A1 | BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |